# Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

> **NCT00704730** · PHASE3 · COMPLETED · sponsor: **Exelixis** · enrollment: 330 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** XL184
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00704730
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2011-10
- **Final completion:** 2020-09
- **Target enrollment:** 330 (ACTUAL)
- **Last updated:** 2021-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00704730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00704730, "Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00704730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*